MSX1

Across TCGA pan-cancer cohorts, MSX1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MSX1 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MSX1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MSX1 expression acts as an unfavorable survival marker.

HNSC, SKCM, and PRAD are the cancer types where MSX1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.163	0.696	.007	24	view →
SKCM	DFS	Median	All	0.192	0.757	.022	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	All	0.103	0.530	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MSX1–HNSC (DFS)

Open the HNSC breakdown →